Acute oromucosal and palmar desquamation: a severe cutaneous adverse reaction to amphotericin and metronidazole

Ryan Connolly, Samantha Russell

DESCRIPTION
A 48-year-old man was started on intravenous amphotericin and metronidazole to treat sepsis in the postoperative period following the repair of a perforated duodenal ulcer. Over a 1 week period he subsequently developed acute epithelial desquamation affecting the oral mucosa (figure 1) and palmar aspects of both hands (figure 2).

Subsequent treatment involved the immediate discontinuation of all non-essential medications including amphotericin and metronidazole and symptomatic relief with the application of regular topical emollients. This resulted in the rapid resolution of symptoms, thereby supporting the diagnosis of a severe cutaneous adverse drug reaction to amphotericin and metronidazole.

DISCUSSION
Systemic antibiotic therapy is a major cause of severe cutaneous adverse reactions—a spectrum of mucocutaneous hypersensitivity disorders including Stevens-Johnson syndrome and toxic epidermal necrolysis.1 Although the exact pathogenesis is not fully understood as yet, these rare but life-threatening disorders are thought to result from cytotoxic T-lymphocyte-mediated keratinocyte apoptosis in genetically predisposed patients.2 3 Severe cases are at further risk of developing systemic manifestations including renal failure and cardiac compromise.

Despite this patient’s underlying morbidity, the selection of an alternative antibiotic and antifungal regimen resulted in the effective treatment of his postoperative sepsis without further precipitation of cutaneous hypersensitivity reactions. He subsequently made a full clinical recovery.

Learning points
- Given their potentially life-threatening nature, clinicians must maintain a high index of suspicion for drug-induced hypersensitivity reactions, thereby ensuring their prompt recognition and appropriate management.
- A detailed medication history should be ascertained in all patients presenting with acute mucocutaneous symptoms.

Competing interests None.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES